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Preventing ischemic complications while limiting 
bleeding risk is the cornerstone when treating patients 
with acute coronary syndrome (ACS) undergoing 
percutaneous coronary intervention (PCI). Questions 
still persist regarding the best strategies for minimizing 
the risk of bleeding events when considering their actual 
negative impact on cardiovascular outcomes and 
mortality [1]. As is often the case, these questions 
become even more challenging in the frail and elderly 
population. During the last decade, there have been 
heated debates over the preferred arterial access (radial 
versus femoral), and antithrombotic regimen (bivali-
rudin versus unfractionated heparin) which are the 
major factors blamed as being responsible for bleeding 
complications. 
The MATRIX (Minimizing Adverse Haemorrhagic 
Events by Transradial Access Site and Systemic 
Implementation of Angiox) trial sought to solve this 
dispute [2,3]. The MATRIX was a research programme 
of three nested randomized multicentre open-label trials 
enrolling 8,404 patients with an ACS for whom PCI 
was planned  (elderly patients aged ≥75 years accounted 
for approximately 25% of the population) [2–4]. The 
three main purposes of the MATRIX investigators were 
to compare the safety and eﬀectiveness of a) radial 
versus femoral access (MATRIX Access); b) bivaliru-
din versus heparin (with optional glycoprotein IIb/IIIa 
inhibitors [GPI]) (MATRIX Antithrombin); and c) post-
PCI bivalirudin infusion versus no post-PCI infusion 
(MATRIX Treatment Duration). Among patients 
assigned to post-PCI bivalirudin infusion, the dose 
could have been either full or reduced at the discretion 
of the treating physician. 
The co-primary endpoints selected for the MATRIX 
Access and the MATRIX Antithrombin were the 
occurrence of major adverse cardiovascular events 
(MACE) (defined as a composite of death, myocardial 
infarction, or stroke), and net adverse clinical events 
(NACE) (a composite of major bleedings [Bleeding 
Academic Research Consortium (BARC) type 3-5] or a 
MACE) up to 30-days. The primary endpoint for 
MATRIX Treatment Duration was a composite of 
urgent target-vessel revascularization, definite stent 
thrombosis, or NACE [2–4]. 
The primary outcomes at 30-days follow-up of the three 
nested trials were published in 2015. The MATRIX 
Access showed that the use of radial access compared to  
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femoral access was of benefit with respect to NACE 
(9.8% vs. 11.7%, rate ratio [RR] 0.83, 95% confidence 
interval [CI] 0.73-0.96; p=0.0092), but not MACE 
(8.8% vs. 10.3%, RR 0.85, 95% CI 0.74-0.99; 
p=0.0307, non-significant at α of 0.025). The reduction 
in NACE was driven by major bleeding unrelated to 
coronary artery bypass graft surgery and all-cause 
mortality [2]. In the MATRIX Antithrombin the 30-
days comparison between bivalirudin and heparin 
showed neutral findings, not significantly reducing the 
rate of MACE (10.3% and 10.9%; RR, 0.94; 95% CI, 
0.81-1.09; p=0.44) nor NACE (11.2% and 12.4%; RR, 
0.89; 95% CI, 0.78-1.03; p=0.12). Similarly, the 
primary composite outcome did not differ between 
patients with post-procedural bivalirudin infusion as 
compared to with no infusion (11.0% and 11.9%; RR, 
0.91; 95% CI, 0.74-1.11; p=0.34) [3]. 
Recently, these findings have been reinforced by the 
publication of the prespecified final 1-year analysis of 
the whole MATRIX programme, confirming the 
previously reported 30-days outcomes in all respects. In 
the MATRIX Access, results showed a carry-over 
benefit for radial access compared to femoral access 
with respect to NACE at 1-year (15.2% vs. 17.2%; RR 
0.87, 95% CI, 0.78-0.97; p=0.0128) mainly driven by a 
reduction in major bleeding events and cardiovascular 
death. For MACE, a trend for reduction was observed 
but remained formally nonsignificant (14.2% vs. 15.7%; 
RR 0.89, 95% CI 0.80-1.00; p=0.0526) [4]. In the 
MATRIX Antithrombin, bivalirudin did not 
significantly reduce MACE (15.8% vs. 16.8%; RR 0.94, 
95% CI, 0.83-1.05; p=0.28) NACE (17.0% vs 18.4%; 
RR 0.91, 95% CI 0.81-1.02; p=0.10) as compared with 
heparin. Besides, post-PCI bivalirudin infusion did not 
significantly lower the rate of the 1-year primary 
endpoint compared with the no-infusion strategy 
(17.4% vs. 17.4%; RR 0.99, 95% 0.84-1.16; p=0.90) 
[4].  
Results from the MATRIX programme argue in clear 
favor of radial over femoral access for reducing adverse 
clinical events in patients with ACS undergoing inva-
sive management [2,4,5] and have been firmly incor-
porated into the European Guidelines that recommended 
radial artery as the preferred vascular access site for any 
PCI [6,7]. 
On the other hand, the comparison between the two 
antithrombin strategies remains difficult to interpret 
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[3,4,8]. Although the MATRIX Antithrombin failed to 
show a significant superiority over bivalirudin with 
respect to NACE or MACE, intriguing messages emerg-
ed from secondary analyses. Firstly, at both 30-days and 
1-year follow-up, bivalirudin was associated with a 
lower rate of all-cause and cardiovascular mortality, and 
bleeding complications [2,4]. Secondly, the use of 
bivalirudin was associated with a reduction in both 
access site and non-access site-related bleeding events 
as compared with heparin [3,4,8], irrespective of the use 
of planned GPI [8]. Thirdly, although a slight increase 
in ischemic events including stent thrombosis was 
recognized using bivalirudin, administration of full-dose 
post-PCI infusion instead of low-dose mitigated the risk 
of thrombotic complications. Finally, at 1-year follow-
up there were trends for both co-primary endpoints 
favoring the use of bivalirudin in patients with impaired 
renal function, generally identifying an older and more 
frail population. Hence generating the hypothesis that 
this treatment might be advantageous in this special 
population [4]. All these considerations keep a door 
open for a bivalirudin-based strategy during PCI and 
warrant further investigations. 
Thus, the MATRIX programme provided prospective 
findings, arising from a large and multinational inves-
tigation, supporting a cause-effect relationship between 
bleeding mitigation strategies and mortality benefit.  
Considering that advanced age per se is amongst the 
most important bleeding risk features [7], every effort 
should be made particularly in elderly patients to apply 
the new gold standards for bleeding prevention in 
current practice. 
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